Goldman Sachs
INMB icon

Goldman Sachs’s INmune Bio INMB Stock Holding History

Goldman Sachs’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302K Sell
185,245
-46,341
-20% -$64.1K ﹤0.01% 6006
2026
Q1 		$262K Buy
231,586
+175,109
+310% +$250K ﹤0.01% 5960
2025
Q4 		$88.1K Buy
56,477
+41,173
+269% +$73.5K ﹤0.01% 6211
2025
Q3 		$31.7K Sell
15,304
-8,294
-35% -$19K ﹤0.01% 6210
2025
Q2 		$54.5K Sell
23,598
-17,118
-42% -$126K ﹤0.01% 5901
2025
Q1 		$318K Sell
40,716
-22,899
-36% -$182K ﹤0.01% 5423
2024
Q4 		$297K Buy
63,615
+30,606
+93% +$160K ﹤0.01% 5499
2024
Q3 		$178K Buy
33,009
+21,352
+183% +$152K ﹤0.01% 5491
2024
Q2 		$103K Sell
11,657
-75,948
-87% -$749K ﹤0.01% 5399
2024
Q1 		$1.03M Buy
+87,605
New +$1.06M ﹤0.01% 4328
2022
Q1 		– Sell
-20,053
Closed -$205K – 6721
2021
Q4 		$205K Buy
+20,053
New +$297K ﹤0.01% 5893

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Goldman Sachs's INMB Position: Q2 2026 in Review

Goldman Sachs reduced its INmune Bio (INMB) stake by 20% in Q2 2026, selling an estimated $64.1K and leaving 185,245 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #6006.

Goldman Sachs first reported a position in INMB in Q4 2021 and has held it in 11 quarters since. The position peaked at $1.03M in Q1 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Goldman Sachs held 185,245 shares of INmune Bio worth $302K as of Q2 2026.
  • Goldman Sachs sold 46,341 INmune Bio shares in Q2 2026, an estimated $64.1K.
  • INmune Bio made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6006 holding.
  • Goldman Sachs first reported a position in INmune Bio in Q4 2021 and has held it in 11 quarters since.
  • Goldman Sachs's INmune Bio position peaked at $1.03M in Q1 2024.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.